

10. BIBLIOGRAFÍA

1. Adams TE, Hockin MF, Mann KG, Everse SJ. 2004. *The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function.* PNAS 101(24): 8918-8923.
2. Bertina RM. 2001. *Genetic aspects of venous thrombosis.* Eur J Obstet Gynecol Reprod Biol 95: 189-192.
3. Castaman G, Faioni E, Tosetto A, Bernardi F. 2003. *The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis.* Journal of Hematology 88(10): 1182-1188.
4. Castoldi E, Brugge JM, Nicolaes GA, Girelli D, Tans G, Rosing J. 2004. *Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.* Blood 103: 4173-4179.
5. Dahlbäck B, Carlsson M, Svensson PJ. 1993. *Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.* Proc Natl Acad Sci USA 90: 1004-1008.
6. Dahlbäck B, Hildebrand B. 1994. *Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.* Proc Natl Acad Sci 91: 1396-1400.
7. Dahlbäck B. 1995. *Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism.* Blood 85: 607-614.

8. Dahlbäck B. 2004. *Anticoagulant factor V and thrombosis risk*. Blood 103 (11): 3995.
9. Faioni EM, Castaman G, Asti D, Lussana F, Rodeghiero F. 2004. *Association of factor V deficiency with factor V HR2*. Haematologica 89(2): 195-200.
10. Faisel F, Romppanen EL, Hiltunen M, Helisalmi S, Laasanen J, Punnonen K, Salonen JT, Heinonen S. 2003. *Susceptibility to pre-eclampsia in Finnish women is associated with R485K polymorphism in the factor V gene, not with Leiden mutation*. European Journal of Human Genetics.
11. Gale AJ, Griffin JH. 2004. *Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va*. PROTEINS: Structure, Function, and Bioinformatics 54: 433-441.
12. Gale AJ, Heeb MJ, Griffin JH. 2000. *The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg 506 and Arg 306 cleavage sites*. Blood 96(2): 585-593.
13. García M, Coma C. 2000. *Características estructurales y funcionales de las plaquetas*. Revista Cubana de Angiología y Circulación Vascular 1(2): 132-141.
14. Hiyoshi M, Arnutti P, Prayoonwiwat W, et al. 1998. *A polymorphism G1628A (R485K) in exon 10 of the coagulation factor V gene may be a risk for thrombosis in the indigenous Thai population*. Thromb Haemost 80: 705-706.
15. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. 1994. *Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families*. Blood 84(4): 1031-1035.

16. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, et al. 1996. *Inherited thrombophilia*. *Thromb Haemost* 76: 824-834.
17. Le W, Yu J, Lu L, Tao R, You B, Cai X, Cao W, Huang W, He R, Chen Z, Gong L. 2000. *Arg485Lys polymorphism of factor V increases the risk of coronary artery disease in a Chinese population*. *Chinese Medical Journal* 113(11): 963-966.
18. Nelson DL, Cox MM. Lehninger principles of biochemistry. 3^a Edición. Worth Publishers. 2000. NY.
19. Nicolaes GA, Dahlbäck B. 2002. *Factor V and thrombotic disease. Description of a janus-faced protein*. *Arterioscler Thromb Vasc Biol* 22: 530-538.
20. Nostrom E, Thorelli E, Dahlbäck B. 2002. *Functional characterization of recombinant FV Hong Kong and FV Cambridge*. *Blood* 100(2): 524-530.
21. Pellequer JL, Gale AJ, Getzoff ED, Griffin JH. 2000. *Three-dimensional model of coagulation factor Va bound to activated protein C*. *Thromb Haemost* 84: 849-857.
22. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kembell-Cook G. 1997. *A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin*. *Blood* 89(7): 2413-2421.
23. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. 1996. *A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis*. *Blood* 88(10): 3698-3703.
24. Rosendaal FR. 1999. *Venous thrombosis: a multicausal disease*. *Lancet* 353: 1167-1173.

25. Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K, Schwarz HP, Tans G. 1995. *Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor Va R506Q by activated protein C.* J Biol Chem 270: 27852-27858.
26. Ruiz-Argüelles GJ, González-Estrada S, Garcés-Eisele J & Ruiz-Argüelles A. 1999. *Primary thrombophilia in México: a prospective study.* American Journal of Hematology 60: 1-5.
27. Ruiz-Argüelles GJ, López-Martínez B, Valdés-Tapia P, Gómez-Rangel JD, Reyes-Núñez V & Garcés-Eisele J. 2005. *Primary thrombophilia in México. V. A comprehensive prospective study indicates that most cases are multifactorial.* American Journal of Hematology 78: 21-26.
28. Ruiz-Argüelles GJ, Poblete-Naredo I, Reyes-Núñez V, Garcés-Eisele J, López-Martínez B & Gómez-Rangel JD. 2004. *Primary thrombophilia in México IV: frequency of the Leiden, Cambridge, Hong Kong, Liverpool, and HR2 haplotype polymorphisms in the factor V gene of a group of thrombophilic Mexican Mestizo patients.* Revista de Investigación Clínica 56(5): 600-604.
29. Ruiz-Argüelles, GJ. Fundamentos de Hematología. 2ª Edición. Editorial Médica Panamericana. 1998. México.
30. Shen L, Dahlbäck B. 1994. *Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa.* The Journal of Biological Chemistry 269 (29): 18735-18738.
31. Singh L, Bukys MA, Beck DO, Kalafatis M. 2003. *Aminoacids Glu 323, Tyr 324, and Val 331 of factor Va heavy chain are essential for expression of cofactor activity.* Journal of Biological Chemistry 278(30): 28335-28345.

32. Steen M, Norstrom EA, Tholander AL, Bolton-Maggs PHB, Mumford A, McVey JH, Tuddenham EGD, Dahlbäck B. 2004. *Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis*. Blood 103 (9): 3381-3387.
33. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 2002. *3-dimensional structure of membrane bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography*. Blood 99(4): 1215-1223.
34. Sun YH, Shen L, Dahlbäck B. 2003. *Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding*. Blood 101 (6): 2277-2284.
35. Thorelli E, Kaufman RJ, Dahlbäck B. 1998. *The C-terminal region of the factor V B domain is crucial for the anticoagulant activity of factor V*. J Biol Chem 273: 16140-16145.
36. Thorelli E, Kaufman RJ, Dahlbäck B. 1999. *Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V*. Blood 93(8): 2552-2558.
37. Villoutreix BO, Covell DG, Blom AM, Wallqvist A, Friedrich U, Dahlbäck B. 2001. *Screening the molecular surface of human anticoagulant protein C. A search for interaction sites*. J Comput Aided Mol Des 15(1): 13-27.
38. Watanabe H, Hamada H, Yamada N, Sohda S, Yamakawa-Kobayashi K, Yoshikawa H, Arinami T. 2002. *Association analysis of nine missense polymorphisms in the coagulation factor V gene with severe preeclampsia in pregnant Japanese women*. Journal of Human Genetics 47: 131-135.

39. Watanabe H, Hamada H, Yamakawa-Kobayashi K, Yoshikawa H, Arinami T. 2001. *Evidence for an association of the R485K polymorphism in the coagulation factor V gene with severe preeclampsia from screening 35 polymorphisms in 27 candidate genes.* Thromb Haemost 86: 1594-1595.
40. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. 1998. *Factor V Cambridge: a new mutation (Arg306Thr) associated with resistance to activated protein C.* Blood 91(4): 1140-1144.
41. Zöller B, Dahlbäck B. 1994. *Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis.* Lancet 343: 1536-1538.